Reneuron Group (RENE)
RENE Share PerformanceMore
|52 week high||3.6750 05/12/16|
|52 week low||1.6000 31/07/17|
|52 week change||-0.9250 (-32.17%)|
|4 week volume||65,186,965 26/07/17|
Media for (RENE)
Latest News« previous» nextMore
07/08/2017 - 15:26 Money Observer
Woodford Patient Capital's performance has picked up over the last three months and Neil Woodford is optimistic. Marina...
07/08/2017 - 15:04 RNS
RNS Number: 3171N ReNeuron Group plc 07 August 2017 AIM: RENE 7 August 2017 ReNeuron Group plc ("ReNeuron" or "the Company") Posting of Annual Report and Accounts and Notice of AGM ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy development company, announces that its Annual Report and Accounts for the year ende...
04/08/2017 - 16:40 RNS
RNS Number: 2036N ReNeuron Group plc 04 August 2017 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this security would still have executed more than a pre-determined p...
04/08/2017 - 16:35 RNS
RNS Number: 2027N ReNeuron Group plc 04 August 2017 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders entered in an individual security's auction call before the executio...
25/07/2017 - 07:00 RNS
RNS Number: 9482L ReNeuron Group plc 25 July 2017 AIM: RENE 25 July 2017 ReNeuron Group plc Appointment of joint broker ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce the appointment of Nplus1 Singer Advisory LLP as joint broker to the Company with immedia...
19/07/2017 - 07:00 RNS
RNS Number: 4399L ReNeuron Group plc 19 July 2017 AIM: RENE 19 July 2017 ReNeuron Group plc Board change ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that Dr Paul Harper , a non-executive director of the business since the Company's flotation on AIM in 200...
29/06/2017 - 07:53 StockMarketWire
ReNeuron has widened its FY pretax loss to 18.2m, from a loss of 12.8m. This followed its operating loss of 19.9m, from 13.7m...
29/06/2017 - 07:00 RNS
RNS Number: 5135J ReNeuron Group plc 29 June 2017 29 June 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Preliminary Results for the Year Ended 31 March 2017 ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce its preliminary results for the year ended 31...
|Dividend yield||0 %|
Equity Research (RENE)
ReNeuron Group plc
The highlight of FY17 was positive Phase II efficacy data from ReNeuron’s PISCES II clinical trial. As this and its other clinical programmes in ophthalmology and its earlier stage exosome platform...
ReNeuron Group plc
Westminster Group (WSG.L) 14.91p £15.15m AGM statement from the supplier of managed security services and technology based security solutions to governments and government agencies, non-governmental...
ReNeuron Group plc
ReNeuron continues to prepare for its Phase III chronic stroke study (due to start in H217) and has indicated that it is making progress with the US/EU regulatory authorities. It intends to submit an...
- 1 of 5
Latest discussion posts More
“Thanks paul. Incidentally, when do you think we will recover a decent sp, assuming of course, a fair wind.”▼
“I don't get papers as all my shares are online so to speak but they should be posted on the website when ready. I am 'disproportionately' invested here too Freddie (and ...”▼
“Double that and your getting closer grizzly and yes I do feel forgotten along being a lot poorer. All that at a time in my life when I need some financial security. Have a ...”▼
Codes & Symbols
|Symbols||RENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE|